PTC Therapeutics Granted Marketing Authorization By EU For Upstaza To Treat AADC Deficiency
(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced Wednesday that Upstaza (eladocagene exuparvovec) was granted marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older.
Upstaza is a one-time gene replacement therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype.
The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
For More Such Health News, visit rttnews.com
FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency
PTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluation
Domino's, Pool Corp. Climb After Buffett's Berkshire Buys Stake
Pound Slides Against Majors
European Shares Slide As Powell Signals Careful Approach To Rate Cuts
FTSE 100 Little Changed After GDP Data; Volex Shares Slump 13%
CAC 40 Drifts Lower As Powell Dashes Rate-cut Hopes
